Anti-dsDNA antibodies that appear to be critical in the pathogenesis of tissue injury are characteristic of systemic lupus erythematosus (SLE). There is a good correlation between anti-dsDNA antibody levels and disease activity. The overall detection rate of these antibodies is approximately 50-55% in SLE patients and about 89% in SLE patients with active renal disease. When they are present in high concentration, anti-dsDNA antibodies are virtually specific for SLE (>90%). Antibodies to dsDNA may disappear with immunosuppressive treatment and during remission. They rarely occur in other autoimmune disorders. Signosis has developed anti-dsDNA ELISA, a sandwich quantitative assay, to screen the presence of serum ds-DNA antibodies IgG.
Autoimmune ELISA kits measure autoimmune antibodies in the serum. It is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes a specific antigen for immobilization on the microtiter wells and anti-human IgG antibody conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two components, resulting in autoimmune antibodies being sandwiched between the solid phase and enzyme-linked antibodies. After incubation, the wells are washed to remove unbound-labeled antibodies. A HRP substrate, TMB, is added to result in the development of a blue color. The color development is then stopped with the addition of Stop Solution changing the color to yellow. The concentration of autoimmune antibodies is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.
LiteratureView user manual
Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production. L Shen, H Zhang, M Caimol, CJ Benike, European journal of Immunology, 2014.